U.S. Markets open in 6 hrs 6 mins

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.54+0.93 (+4.11%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.61
Open22.82
Bid22.25 x 1300
Ask24.75 x 1200
Day's Range22.36 - 23.98
52 Week Range17.51 - 38.49
Volume236,353
Avg. Volume178,638
Market Cap1.182B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-10.27
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.88
  • Motley Fool

    Is Now the Time to Bet on Arcutis Biotherapeutics?

    Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted?

  • GlobeNewswire

    Arcutis to Present at Upcoming Investor Conferences

    WESTLAKE VILLAGE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, today announced that Arcutis management will participate in two upcoming investor conferences in September. Details for the company’s participation are as follows: Morgan Stanley

  • GlobeNewswire

    Arcutis Announces Appointment of Keith Leonard to Board of Directors

    Keith R. Leonard Jr. Arcutis Announces Appointment of Keith Leonard to Board of Directors WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Keith R. Leonard Jr. has been appointed to the Arcutis Board of Dir